Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy

Background: Nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) frequently develop low skeletal muscle mass (SMM), but, little is known about the impacts of low SMM on health-related quality of life (QOL).Methods: We retrospectively assessed 56 patients with locoreg...

Full description

Bibliographic Details
Main Authors: Xin Hua, Jun-Fang Liao, Shan Liu, Jun Zhang, Han-Ying Huang, Wen Wen, Zhi-Qing Long, Wen-Wen Zhang, Ling Guo, Huan-Xin Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Nutrition
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnut.2019.00195/full
id doaj-3a3b754be7dd440180e5204bc0dfd323
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Xin Hua
Xin Hua
Jun-Fang Liao
Shan Liu
Jun Zhang
Jun Zhang
Han-Ying Huang
Han-Ying Huang
Wen Wen
Wen Wen
Zhi-Qing Long
Zhi-Qing Long
Wen-Wen Zhang
Wen-Wen Zhang
Ling Guo
Ling Guo
Huan-Xin Lin
Huan-Xin Lin
spellingShingle Xin Hua
Xin Hua
Jun-Fang Liao
Shan Liu
Jun Zhang
Jun Zhang
Han-Ying Huang
Han-Ying Huang
Wen Wen
Wen Wen
Zhi-Qing Long
Zhi-Qing Long
Wen-Wen Zhang
Wen-Wen Zhang
Ling Guo
Ling Guo
Huan-Xin Lin
Huan-Xin Lin
Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
Frontiers in Nutrition
nasopharyngeal carcinoma
low skeletal muscle mass
pain
quality of life
concurrent chemoradiotherapy
author_facet Xin Hua
Xin Hua
Jun-Fang Liao
Shan Liu
Jun Zhang
Jun Zhang
Han-Ying Huang
Han-Ying Huang
Wen Wen
Wen Wen
Zhi-Qing Long
Zhi-Qing Long
Wen-Wen Zhang
Wen-Wen Zhang
Ling Guo
Ling Guo
Huan-Xin Lin
Huan-Xin Lin
author_sort Xin Hua
title Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
title_short Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
title_full Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
title_fullStr Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
title_full_unstemmed Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent Chemoradiotherapy
title_sort low skeletal muscle mass impairs quality of life in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy
publisher Frontiers Media S.A.
series Frontiers in Nutrition
issn 2296-861X
publishDate 2020-01-01
description Background: Nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) frequently develop low skeletal muscle mass (SMM), but, little is known about the impacts of low SMM on health-related quality of life (QOL).Methods: We retrospectively assessed 56 patients with locoregionally advanced NPC enrolled in a prospective trial. Low SMM was determined on routine computed tomography simulation (CT-sim) scans taken before radiotherapy, at the third cervical (C3) vertebral level with validated sex-specific cutoffs. QOL was assessed using the World Health Organization Quality of Life Questionnaire-100 at baseline and after 3 weeks. Pain was scored every 24 h using a numerical rating scale (NRS). Characteristics related to low SMM were identified by logistic regression. The chi-square test was used to examine the association of low SMM with QOL and pain.Results: Of the 56 participants (mean age 44.20 ± 10.93 years), over half (60.71%) developed low SMM. Patients with low SMM were more likely to be older (P = 0.035), male (P = 0.066), have a lower body-mass index (BMI; P = 0.091), and have a higher pain score (P = 0.001). Older age (hazard ratio [HR] = 1.788, P = 0.016), being male (HR = 3.145, P = 0.010), lower BMI (HR = 0.761, P = 0.033), and lower prognostic nutritional index (HR = 0.186, P = 0.034) were associated with higher risk of low SMM. Low SMM was associated with poorer baseline QOL scores (P = 0.072), especially in the physical domain (P = 0.002) and its three facets: pain (P = 0.003), energy (P = 0.021), and sleep (P = 0.007). Low SMM was also associated with significantly worse QOL scores (P = 0.006) at 3 weeks, especially in the physical (P = 0.002), psychological (P = 0.046), independence (P = 0.003), social domains (P = 0.023), and in general health condition (P = 0.043). For pain score, low SMM group had worse overall changes from baseline to week 3 (P = 0.011).Conclusions: The incidence of low SMM, as evaluated using routine CT-sim scans, is high in patients receiving CCRT for locoregionally advanced NPC. Low SMM results in poorer QOL and higher pain scores, which underscores the requirement for nutritional and functional interventions to address low SMM early in the treatment course.
topic nasopharyngeal carcinoma
low skeletal muscle mass
pain
quality of life
concurrent chemoradiotherapy
url https://www.frontiersin.org/article/10.3389/fnut.2019.00195/full
work_keys_str_mv AT xinhua lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT xinhua lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT junfangliao lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT shanliu lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT junzhang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT junzhang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT hanyinghuang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT hanyinghuang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT wenwen lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT wenwen lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT zhiqinglong lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT zhiqinglong lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT wenwenzhang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT wenwenzhang lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT lingguo lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT lingguo lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT huanxinlin lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
AT huanxinlin lowskeletalmusclemassimpairsqualityoflifeinnasopharyngealcarcinomapatientstreatedwithconcurrentchemoradiotherapy
_version_ 1725083335712047104
spelling doaj-3a3b754be7dd440180e5204bc0dfd3232020-11-25T01:32:05ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2020-01-01610.3389/fnut.2019.00195497994Low Skeletal Muscle Mass Impairs Quality of Life in Nasopharyngeal Carcinoma Patients Treated With Concurrent ChemoradiotherapyXin Hua0Xin Hua1Jun-Fang Liao2Shan Liu3Jun Zhang4Jun Zhang5Han-Ying Huang6Han-Ying Huang7Wen Wen8Wen Wen9Zhi-Qing Long10Zhi-Qing Long11Wen-Wen Zhang12Wen-Wen Zhang13Ling Guo14Ling Guo15Huan-Xin Lin16Huan-Xin Lin17State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Radiation Oncology, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Radiotherapy, Sun Yat-sen University Cancer Center, Guangzhou, ChinaBackground: Nasopharyngeal carcinoma (NPC) patients receiving concurrent chemoradiotherapy (CCRT) frequently develop low skeletal muscle mass (SMM), but, little is known about the impacts of low SMM on health-related quality of life (QOL).Methods: We retrospectively assessed 56 patients with locoregionally advanced NPC enrolled in a prospective trial. Low SMM was determined on routine computed tomography simulation (CT-sim) scans taken before radiotherapy, at the third cervical (C3) vertebral level with validated sex-specific cutoffs. QOL was assessed using the World Health Organization Quality of Life Questionnaire-100 at baseline and after 3 weeks. Pain was scored every 24 h using a numerical rating scale (NRS). Characteristics related to low SMM were identified by logistic regression. The chi-square test was used to examine the association of low SMM with QOL and pain.Results: Of the 56 participants (mean age 44.20 ± 10.93 years), over half (60.71%) developed low SMM. Patients with low SMM were more likely to be older (P = 0.035), male (P = 0.066), have a lower body-mass index (BMI; P = 0.091), and have a higher pain score (P = 0.001). Older age (hazard ratio [HR] = 1.788, P = 0.016), being male (HR = 3.145, P = 0.010), lower BMI (HR = 0.761, P = 0.033), and lower prognostic nutritional index (HR = 0.186, P = 0.034) were associated with higher risk of low SMM. Low SMM was associated with poorer baseline QOL scores (P = 0.072), especially in the physical domain (P = 0.002) and its three facets: pain (P = 0.003), energy (P = 0.021), and sleep (P = 0.007). Low SMM was also associated with significantly worse QOL scores (P = 0.006) at 3 weeks, especially in the physical (P = 0.002), psychological (P = 0.046), independence (P = 0.003), social domains (P = 0.023), and in general health condition (P = 0.043). For pain score, low SMM group had worse overall changes from baseline to week 3 (P = 0.011).Conclusions: The incidence of low SMM, as evaluated using routine CT-sim scans, is high in patients receiving CCRT for locoregionally advanced NPC. Low SMM results in poorer QOL and higher pain scores, which underscores the requirement for nutritional and functional interventions to address low SMM early in the treatment course.https://www.frontiersin.org/article/10.3389/fnut.2019.00195/fullnasopharyngeal carcinomalow skeletal muscle masspainquality of lifeconcurrent chemoradiotherapy